Daptomycin for the treatment of daptomycin nonsusceptible Enterococcus faecium bacteremia

Year 2014, , 36 - 38, 01.03.2014

Dilek Yildiz Sevgi Alper Gunduz Ahmet Şanlı Konuklar Murat Musluman Feyzullah Tuncer Okan Derin Banu Bayraktar Nuray Uzun

https://doi.org/10.5799/ahinjs.02.2014.01.0122

Abstract

Dilek Yildiz Sevgi, Alper Gunduz, Ahmet Şanlı Konuklar, Murat Musluman, Feyzullah Tuncer, Okan Derin, Banu Bayraktar, Nuray Uzun The best therapeutic options for serious infections due to daptomycin nonsusceptible Enterococcus faecium (DNSE) remain unclear. We report the use of daptomycin for the treatment of DNSE bacteremia. To our knowledge, it is the fırst case of DNSE infection which successfully treated with daptomycin monotherapy in the literature.

Keywords

Enterococcus, bloodstream infection, daptomycin

Daptomycin for the treatment of daptomycin nonsusceptible Enterococcus faecium bacteremia

Abstract

Daptomisine duyarlı olmayan Enterococcus faecium (DNSE)’a bağlı ciddi enfeksiyonlarda en iyi tedavi seçeneği belirsizdir. Burada DNSE bakteriyemisi olan bir olguda daptomisin kullanımı tecrübemizi paylaştık. Bildiğimiz kadarı ile literatürde daptomisin monoterapisi ile başarılı tedavi edilen ilk olgudur

Keywords

Enterokoklar, kanakımı enfeksiyonu, daptomisin

References

• Diaz Granados CA, Zimmer SM, Klein M et, al. Comparison of mortality associated with vancomycin-resistant and van- comycin-susceptible enterococcal bloodstream infections: a metaanalysis. Clin Infect Dis 2005;41:327-333.
• Murray BE. Treatment of enterococcal infections. In: UpTo Date, Sexton DJ (ed), 2013.
• Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infec- tions. Antimicrob Agents Chemother 2013;57:4190-4196.
• Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activ- ity of daptomycin. Antimicrob Agents Chemother 2004;48:63- 68.
• Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clini- cians. Clin Infect Dis 2011;52:228-234.
• Cesur S, Irmak H, Simşek H, et al. Evaluation of antibiotic susceptibilities and VISA-VRSA rates among MRSA strains isolated from hospitalized patients in intensive care units of hospitals in seven provinces of Turkey. Mikrobiyol Bul 2012;46:352-358.
• Yilmaz G, Eruz E, Coşkun B, et al. Ülkemizden ilk duyarlı ol- mayan (non-susceptible) S. aureus enfeksiyonu. EKMUD Congress,. Istanbul, Turkey May 2012.
• Grim SA, Hong I, Freeman J, et al. Daptomycin for the treat- ment of vancomycin-resistant enterococcal infections. J Anti- microb Chemother 2009;63:414-416.
• Gallagher JC, Perez ME, Marino EA, et al. Daptomycin ther- apy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009;29:792-799.
• Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009;33:543-548.
• Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A po- tential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010;65:1126-1136.
• Clinical Laboratory Standards Institute: Performance stan- dards for antimicrobial susceptibility testing. 20th Informa- tional Supplement. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
• King EA, McCoy D, Desai S, et al. Vancomycin-resistant en- terococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother 2011;66:2112-2118.
• Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomy- cin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318-1323.
• Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharma- cokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245- 3249.